Literature DB >> 12794167

Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.

Mala Chakraborty1, Scott I Abrams, Kevin Camphausen, Kebin Liu, Tamalee Scott, C Norman Coleman, James W Hodge.   

Abstract

CD8(+) CTL play important roles against malignancy in both active and passive immunotherapy. Nonetheless, the success of antitumor CTL responses may be improved by additional therapeutic modalities. Radiotherapy, which has a long-standing use in treating neoplastic disease, has been found to induce unique biologic alterations in cancer cells affecting Fas gene expression, which, consequently, may influence the overall lytic efficiency of CTL. Here, in a mouse adenocarcinoma cell model, we examined whether exposure of these tumor cells to sublethal doses of irradiation 1) enhances Fas expression, leading to more efficient CTL killing via Fas-dependent mechanisms in vitro; and 2) improves antitumor activity in vivo by adoptive transfer of these Ag-specific CTL. Treatment of carcinoembryonic Ag-expressing MC38 adenocarcinoma cells with irradiation (20 Gy) in vitro enhanced Fas expression at molecular, phenotypic, and functional levels. Furthermore, irradiation sensitized these targets to Ag-specific CTL killing via the Fas/Fas ligand pathway. We examined the effect of localized irradiation of s.c. growing tumors on the efficiency of CTL adoptive immunotherapy. Irradiation caused up-regulation of Fas by these tumor cells in situ, based on immunohistochemistry. Moreover, localized irradiation of the tumor significantly potentiated tumor rejection by these carcinoembryonic Ag-specific CTL. Overall, these results showed for the first time that 1) regulation of the Fas pathway in tumor cells by irradiation plays an important role in their sensitization to Ag-specific CTL; and 2) a combination regimen of tumor-targeted irradiation and CTL promotes more effective antitumor responses in vivo, which may have implications for the combination of immunotherapy and radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794167     DOI: 10.4049/jimmunol.170.12.6338

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  189 in total

Review 1.  The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant.

Authors:  Kobe Reynders; Tim Illidge; Shankar Siva; Joe Y Chang; Dirk De Ruysscher
Journal:  Cancer Treat Rev       Date:  2015-03-28       Impact factor: 12.111

2.  Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.

Authors:  James W Hodge; Hadley J Sharp; Sofia R Gameiro
Journal:  Cancer Biother Radiopharm       Date:  2012-01-27       Impact factor: 3.099

Review 3.  DNA Damage and Repair Biomarkers of Immunotherapy Response.

Authors:  Kent W Mouw; Michael S Goldberg; Panagiotis A Konstantinopoulos; Alan D D'Andrea
Journal:  Cancer Discov       Date:  2017-06-19       Impact factor: 39.397

Review 4.  The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors:  James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 5.  Clinical development of Listeria monocytogenes-based immunotherapies.

Authors:  Dung T Le; Thomas W Dubenksy; Dirk G Brockstedt
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

6.  A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Authors:  Mahsa Mohebtash; Kwong-Yok Tsang; Ravi A Madan; Ngar-Yee Huen; Diane J Poole; Caroline Jochems; Jacquin Jones; Theresa Ferrara; Christopher R Heery; Philip M Arlen; Seth M Steinberg; Mary Pazdur; Myrna Rauckhorst; Elizabeth C Jones; William L Dahut; Jeffrey Schlom; James L Gulley
Journal:  Clin Cancer Res       Date:  2011-11-08       Impact factor: 12.531

Review 7.  Exercise as Adjunct Therapy in Cancer.

Authors:  Kathleen A Ashcraft; Allison Betof Warner; Lee W Jones; Mark W Dewhirst
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

Review 8.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

9.  Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer.

Authors:  Ravi A Madan; Thomas Schwaab; James L Gulley
Journal:  J Natl Compr Canc Netw       Date:  2012-12-01       Impact factor: 11.908

10.  Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?

Authors:  Abigail T Berman; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.